Diamond Edge Capital Partners

Diamond Edge Ventures (DEV) is the corporate venture capital arm of the Mitsubishi Chemical Group (MCG), established in 2018 to invest in high-potential startups globally. The firm focuses on sectors strategic to its parent company, specifically healthcare, industrial technology, and sustainability. In the life sciences and healthcare space, DEV targets innovative companies in biotechnology, drug discovery, and medical technology that can benefit from MCG's extensive global network and technical expertise. Headquartered in Silicon Valley with a presence in Tokyo, the firm acts as a bridge between startups and the various business units of Mitsubishi Chemical, including its pharmaceutical operations under Mitsubishi Tanabe Pharma.